Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28886965 | 0.84 | CYP4F2 (0.41) | MEN1KMT2AKDM4EDUSP3LMNA | |
| SCHEMBL5919694 | 0.80 | GPR84 (0.39) | MEN1KMT2AKDM4EDUSP3LMNA | |
| SCHEMBL15876485 | 0.80 | MEN1 (0.42) | MEN1KMT2AKDM4EDUSP3LMNA | |
| SCHEMBL990660 | 0.80 | GPR84 (0.39) | MEN1KMT2AKDM4EDUSP3LMNA | |
| SCHEMBL39604 | 0.79 | GPR84 (0.41) | MEN1KMT2AKDM4EDUSP3LMNA | |
| SCHEMBL2139320 | 0.79 | KDM4E (0.42) | MEN1KMT2AKDM4EDUSP3LMNA | |
| SCHEMBL297150 | 0.78 | MEN1 (0.58) | MEN1KMT2AKDM4EDUSP3LMNA | |
| SCHEMBL297149 | 0.76 | MAPT (0.54) | MAPT | |
| SCHEMBL11166992 | 0.75 | CYP4F2 (0.35) | MEN1KMT2AKDM4EDUSP3LMNA | |
| SCHEMBL1123301 | 0.75 | GPR84 (0.55) | MEN1KMT2AKDM4EDUSP3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558467-B1 | STABILIZATION OF COSMETIC COMPOSITIONS COMPRISING FISH OILS AND HYDROXYLATED FATTY ACIDS AND/OR ITS DERIVATIVES | UNILEVER IP HOLDINGS B V (NL) | 2023-06-07 | — | — | EP | claimed |
| US-10166235-B2 | Kinetin/zeatin topical formulation | DOW PHARMACEUTICAL SCIENCES, INC. (US) | 2019-01-01 | — | — | US | claimed |
| US-20180311246-A1 | KINETIN/ZEATIN TOPICAL FORMULATION | JPMORGAN CHASE BANK, N.A. | 2018-11-01 | — | — | US | claimed |
| US-9925194-B2 | Kinetin/zeatin topical formulation | DOW PHARMACEUTICAL SCIENCES, INC. (US) | 2018-03-27 | — | — | US | claimed |
| US-20170209453-A1 | KINETIN/ZEATIN TOPICAL FORMULATION | JPMORGAN CHASE BANK, N.A. | 2017-07-27 | — | — | US | claimed |
| US-9616132-B2 | Kinetin/zeatin topical formulation | DOW PHARMACEUTICAL SCIENCES, INC. (US) | 2017-04-11 | — | — | US | claimed |
| US-20140271826-A1 | KINETIN/ZEATIN TOPICAL FORMULATION | DOW PHARMACEUTICAL SCIENCES, INC. (US) | 2014-09-18 | — | — | US | claimed |
| US-20250332084-A1 | PEPTIDE COMPOSITION AND RESPECTIVE USES | UNIVERSIDADE DO MINHO (PT) | 2025-10-30 | — | — | US | disclosed |
| US-20250319008-A1 | HAIR COMPOSITIONS USES AND METHODS THEREOF | FUNCTION INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12383484-B2 | Peptide composition and respective uses | UNIVERSIDADE DO MINHO (PT) | 2025-08-12 | — | — | US | disclosed |
| WO-2025137392-A1 | CONDITIONER COMPOSITIONS, CLEANSER COMPOSITIONS AND METHODS OF USING THE SAME | K18, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4543406-A1 | HAIR CLEANSER COMPOSITION, METHODS AND USES THEREOF | K18, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| EP-4543547-A2 | DETOX HAIR AND SCALP CLEANSER COMPOSITION, METHODS AND USES THEREOF | K18, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| EP-1203141-A1 | LINKAGE OF AGENTS TO TISSUE | Pericor Science, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1202706-A1 | LYSINE OXIDASE LINKAGE OF AGENTS TO TISSUE | Pericor Science, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2002007707-A2 | LINKAGE OF AGENTS USING MICROPARTICLES | PERICOR SCIENCE, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001007009-A1 | LYSINE OXIDASE LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001006829-A2 | LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-0768867-A1 | DOSAGE FORM FOR ADMINISTERING DRUG IN LIQUID FORMULATION | ALZA CORPORATION (US) | 1997-04-23 | — | — | EP | disclosed |
| WO-1995034285-A1 | DOSAGE FORM FOR ADMINISTERING DRUG IN LIQUID FORMULATION | ALZA CORPORATION (US) | 1995-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319008-A1 | HAIR COMPOSITIONS USES AND METHODS THEREOF | CUTA, KRT18, NACA | MEN1 3801/4885KMT2A 2443/4885KDM4E 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.